Prophylactic HPV Vaccines and Prevention of Cervical Intraepithelial Neoplasia

Heitmann, Erica; Harper, Diane M.

doi:10.1007/s13669-012-0017-4

Cited by 7 publications

(13 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPV 16 is identified as the dominant sub-type (62%) in squamous cell carcinoma (SCC) and cervical adenocarcinoma (CAC) in all countries and HPV 18 has a global frequency of 8% [11,17]. Yet cervical cancer rates vary significantly between countries.…”

Section: Reviewmentioning

confidence: 99%

“…HPV natural history shows that only 5% of HPV infections progress to CIN 2 or 3 within 3 years [11]. Of this 5% many CIN 3 lesions will regress (80%) and approximately 20% progress to invasive carcinoma within 5 years.…”

Section: Reviewmentioning

confidence: 99%

“…Of this 5% many CIN 3 lesions will regress (80%) and approximately 20% progress to invasive carcinoma within 5 years. Of this 20% only 40% progress to invasive carcinoma within 30 years [11]. This suggests that the majority of pre-cancerous lesions in young women do not lead to cancer later in life and hence they are not an accurate end-point for determining how much cervical cancer can be prevented by an HPV vaccine.…”

Section: Reviewmentioning

confidence: 99%

“…Clinical trials to test the hypothesis that the quadrivalent HPV vaccine would be effective against cervical cancer, and not just the prevention of HPV 16/18 infection, were started in phase 3 trials in 2003 [10,11]. These trials investigated pre-cancerous lesions in 12,167 women (15–26 years old) and were completed in 2007 [10].…”

Section: Introductionmentioning

confidence: 99%

“…Yet the quadrivalent HPV vaccine was approved for the European and US market in 2006 [12,13]. The HPV vaccine, Gardasil® was developed and marketed to women as an effective prevention for cervical cancer after only 4 years of testing for efficacy against pre-cancerous lesions [11,14]. …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery

Wilyman

2013

Infect Agents Cancer

View full text Add to dashboard Cite

Pap screening combined with loop electrosurgical excision procedures (LEEP) is almost 100% effective in preventing cervical cancer mortality yet many countries with these procedures have now implemented broad HPV vaccination programs. HPV vaccines have not been demonstrated to be more effective or safer than Pap screening in the prevention of cervical cancer and Pap screening will still be required even in vaccinated women. The HPV vaccine costs Au$450 per person and it does not protect against ~30% of cancer. This investigation analyses the cost-effectiveness of using the HPV vaccine in countries where Pap screening and surgical procedures have already reduced cervical cancer mortality to very low rates. Cost-effectiveness of vaccination programs is being determined by mathematical models which are founded on many assumptions. It is necessary to examine the rigor of these assumptions to be certain of the health benefits that are predicted. In 2002 scientists concluded that HPV 16 and 18 were the central and independent cause of most cervical cancer. This conclusion was based on molecular technology. If HPV 16 and 18 infections are the central and independent cause of most cervical cancer then the incidence of HPV 16 and 18 should vary with the incidence and mortality of cervical cancer worldwide. This correlation does not exist. It is also observed that the majority of HPV 16/18 infections do not lead to cervical cancer. This indicates that other etiological or ‘risk’ factors are necessary for persistent HPV infection to progress to cancer. The benefits of HPV vaccines have been determined by using pre-cancerous lesions in young women as a surrogate for cervical cancer. This surrogate is found to be inadequate as an end-point for cervical cancer. Clinical trials have only provided speculative benefits for the efficacy of HPV vaccines against cancer and the long-term risks of the vaccine have not been established. Pap screening will still be required in vaccinated women hence HPV vaccination programs are not cost-effective, and may do more harm than good, in countries where regular Pap screening and surgery has already reduced the burden of this disease.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%